Nanexa ABFRA:40M +0.99%53 Pretax Margin % is -857.89% as of Mar. 2026. GuruFocus rates FRA:40M with a GF Score™ of 53/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Nanexa AB ranks worse than 86.13% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Nanexa AB's Pre-Tax Income for the
three
months ended in Mar. 2026 was €-1.30 Mil. Nanexa AB's Revenue for the
three
months ended in Mar. 2026 was €0.15 Mil. Therefore, Nanexa AB's pretax margin for the quarter that ended in Mar. 2026 was -857.89%.
The historical rank and industry rank for Nanexa AB's Pretax Margin % or its related term are showing as below:
FRA:40M'
s Pretax Margin % Range Over the Past 10 Years
Min: -7591.43 Med: -1217.68 Max: -31.8
Current: -47.36
FRA:40M's Pretax Margin % is ranked worse than 86.13% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs FRA:40M: -47.36
Nanexa AB (FRA:40M) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Nanexa AB Pretax Margin % Related Terms
Nanexa AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Nanexa AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Nanexa AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanexa AB (FRA:40M) has a Pretax Margin % of -857.89% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nanexa AB and its competitors. According to the industry distribution chart, Nanexa AB ranks #820 out of 952 companies in the Drug Manufacturers industry, placing it in the top 86.1%.
Is Nanexa AB's Pretax Margin % too high?
Nanexa AB's current Pretax Margin % is -857.89%. Based on the distribution chart, Nanexa AB ranks #820 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nanexa AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nanexa AB ranks #820 out of 952 companies for Pretax Margin %. This places Nanexa AB in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current Pretax Margin % is -857.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.31 — trading 79.7% above its estimated fair value. The current Pretax Margin % is -857.89%. Nanexa AB's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current Pretax Margin % is -857.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.31 is trading 79.7% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
Pretax Margin %: -857.89%
GF Value™: €0.17 vs. price of €0.31 (79.7% above fair value)
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
53GF Score
Get the complete analysis for FRA:40M
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
